信达生物伊匹木单抗N01注射液获国家药监局批准上市

Core Viewpoint - The announcement by Innovent Biologics regarding the approval of IBI310 (Ipilimumab N01 injection) by the NMPA marks a significant advancement in the treatment of MSI-H or dMMR colorectal cancer patients, indicating a potential growth opportunity in the oncology market in China [1] Group 1 - Innovent Biologics has received approval from the National Medical Products Administration (NMPA) for IBI310, a CTLA-4 monoclonal antibody [1] - IBI310 is to be used in combination with Sintilimab for neoadjuvant therapy in patients with resectable stage IIB-III MSI-H or dMMR colorectal cancer [1] - This approval highlights the company's commitment to addressing unmet medical needs in oncology and expanding its product portfolio [1]